Proteomics-Based Analysis of Clinical Significance of Roundabout Guidance Receptor 4 and Protocadherin 12 in Screening,Diagnosis,and Staging of Colorectal Cancer

Jianchun FAN; Xinran CAO; Chunbaixue YANG; Bin ZHANG; Yixuan ZHANG; Lei XIA; Xueliang WU

doi:10.3881/j.issn.1000-503X.16558

PDF(3665 KB)

Acta Academiae Medicinae Sinicae ›› 2025, Vol. 47 ›› Issue (6) : 910-920. DOI: 10.3881/j.issn.1000-503X.16558

Proteomics-Based Analysis of Clinical Significance of Roundabout Guidance Receptor 4 and Protocadherin 12 in Screening,Diagnosis,and Staging of Colorectal Cancer

Jianchun FAN ¹ ,
Xinran CAO ² ,
Chunbaixue YANG ³ ,
Bin ZHANG ² ,
Yixuan ZHANG ⁴ ,
Lei XIA ⁵ ,
Xueliang WU ¹^,⁶

Author information +

History +

Abstract

Objective To explore the clinical significance of roundabout guidance receptor 4(ROBO4) and protocadherin 12(PCDH12) in the human serum in the screening,diagnosis,and staging of colorectal cancer(CRC) through proteomics and bioinformatics,thus providing a novel screening method with high specificity,sensitivity,and accuracy for the early screening and diagnosis of CRC in clinical practice. Methods Proteomics and bioinformatics approaches were employed to select the target proteins ROBO4 and PCDH12,and the correlation between ROBO4 and PCDH12 was analyzed.A total of 121 CRC patients(cancer group),112 patients with polyps(polyp group),and 108 healthy volunteers(normal group) who received treatment or physical examination from January 2023 to June 2024 were enrolled in this study.ELISA was employed to determine the expression levels of ROBO4,PCDH12,carcinoembryonic antigen(CEA),and carbohydrate antigen 199(CA199) in the samples of each group.The expression levels of the four proteins in the serum were compared among the three groups of patients mentioned above,and the relationships of the serum levels of ROBO4 and PCDH12 with the pathological characteristics of the CRC patients were analyzed.Furthermore,the receiver operating characteristic(ROC) curves were established to evaluate the diagnostic efficacy of the serum levels of ROBO4 and PCDH12 for CRC patients in early and progressive stages. Results The target proteins ROBO4 and PCDH12 were screened out through proteomics.Bioinformatics analysis showed that ROBO4 and PCDH12 were highly expressed in CRC patients.Further correlation analysis revealed a positive correlation between ROBO4 and PCDH12 in CRC(R=0.870,P<0.001).The ELISA results of clinical samples showed that compared with the normal group and polyp group,the cancer group presented elevated expression levels of ROBO4 and PCDH12(all P<0.001).There was no statistically significant difference in the expression level of ROBO4 or PCDH12 between the normal group and the polyp group(P=0.586,P=0.550).The ROC curves showed that the diagnostic efficacy of ROBO4,PCDH12,and ROBO4+PCDH12 was 0.787,0.757,and 0.812,respectively,all of which were higher than the diagnostic efficacy of CEA and CA199.Further analysis of serum levels of ROBO4 and PCDH12 with the pathological data of CRC showed that the serum level of ROBO4 was correlated with differentiation degree(P=0.013),pathological stage(P=0.002),lymph node metastasis(P=0.001),and distant metastasis(P=0.026).The serum level of PCDH12 was correlated with differentiation degree(P=0.043),pathological stage(P=0.012),and lymph node metastasis(P=0.001).The ROC curves showed that the diagnostic efficacy of ROBO4,PCDH12,and ROBO4+PCDH12 was 0.637,0.758,and 0.787 for early CRC and 0.872,0.757,and 0.882 for progressive CRC,respectively. Conclusions The serum levels of ROBO4 and PCDH12 demonstrate high diagnostic efficacy for CRC patients and are correlated with the pathological features of CRC.The two proteins are expected to be novel serum biomarkers for the diagnosis and screening of CRC.

Key words

colorectal cancer / roundabout guidance receptor 4 / protocadherin 12 / diagnostic efficacy

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Jianchun FAN , Xinran CAO , Chunbaixue YANG , et al . Proteomics-Based Analysis of Clinical Significance of Roundabout Guidance Receptor 4 and Protocadherin 12 in Screening,Diagnosis,and Staging of Colorectal Cancer[J]. Acta Academiae Medicinae Sinicae. 2025, 47(6): 910-920 https://doi.org/10.3881/j.issn.1000-503X.16558

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

[1]	Sedlak JC, Yilmaz ÖH, Roper J. Metabolism and colorectal cancer[J]. Annu Rev Pathol, 2023, 18:467-492.DOI:10.1146/annurev-pathmechdis-031521-041113. Cited in this article [1]

[2]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.DOI:10.3322/caac.21660. Cited in this article [2]

[3]	Siegel RL, Wagle NS, Cercek A, et al. Colorectal cancer statistics,2023[J]. CA Cancer J Clin, 2023, 73(3):233-254.DOI:10.3322/caac.21772. Cited in this article [5]

[4]	Gobert AP, Latour YL, Asim M, et al. Protective role of spermidine in colitis and colon carcinogenesis[J]. Gastroenterology, 2022, 162(3):813-827.e8.DOI:10.1053/j.gastro.2021.11.005. Cited in this article [1]

[5]	Zhang Y, Wang Y, Zhang B, et al. Methods and biomarkers for early detection,prediction,and diagnosis of colorectal cancer[J]. Biomed Pharmacother, 2023, 163:114786.DOI:10.1016/j.biopha.2023.114786. Cited in this article [1]

[6]	Nooredinvand HA, Poullis A. Emerging role of colorectal mucus in gastroenterology diagnostics[J]. World J Gastroenterol, 2022, 28(12):1220-1225.DOI:10.3748/wjg.v28.i12.1220. Cited in this article [1]

[7]	Hanna M, Dey N, Grady WM. Emerging tests for noninvasive colorectal cancer screening[J]. Clin Gastroenterol Hepatol, 2023, 21(3):604-616.DOI:10.1016/j.cgh.2022.12.008. Cited in this article [2]

[8]	Imperiale TF, Ransohoff DF, Itzkowitz SH. Multitarget stool DNA testing for colorectal-cancer screening[J]. N Engl J Med, 2014, 371(2):187-188.DOI:10.1056/NEJMc1405215. Cited in this article [1]

[9]	Barnell EK, Wurtzler EM, La Rocca J, et al. Multitarget stool RNA test for colorectal cancer screening[J]. JAMA, 2023, 330(18):1760-1768.DOI:10.1001/jama.2023.22231. Cited in this article [1]

[10]	Bosch LJW, de Wit M, Pham TV, et al. Novel stool-based protein biomarkers for improved colorectal cancer screening:a case-control study[J]. Ann Intern Med, 2017, 167(12):855-866.DOI:10.7326/m17-1068. Cited in this article [1]

[11]	Iadsee N, Chuaypen N, Techawiwattanaboon T, et al. Identification of a novel gut microbiota signature associated with colorectal cancer in Thai population[J]. Sci Rep, 2023, 13(1):6702.DOI:10.1038/s41598-023-33794-9. Cited in this article [1]

[12]	Nikanjam M, Kato S, Kurzrock R. Liquid biopsy:current technology and clinical applications[J]. J Hematol Oncol, 2022, 15(1):131.DOI:10.1186/s13045-022-01351-y. Cited in this article [1]

[13]	Marcuello M, Vymetalkova V, Neves RPL, et al. Circulating biomarkers for early detection and clinical management of colorectal cancer[J]. Mol Aspects Med, 2019, 69:107-122.DOI:10.1016/j.mam.2019.06.002. Cited in this article [1]

[14]	Chen YK, Hou HA, Tang JL, et al. Clinical and prognostic implications of roundabout 4(ROBO4) in adult patients with acute myeloid leukemia[J]. PLoS One, 2015, 10(3):e0119831.DOI:10.1371/journal.pone.0119831. Cited in this article [1]

[15]	Feng X, Zhang M, Meng J, et al. Correlating transcriptional networks to papillary renal cell carcinoma survival:a large-scale coexpression analysis and clinical validation[J]. Oncol Res, 2020, 28(3):285-297.DOI:10.3727/096504020x15791676105394. Cited in this article [4]

[16]	Pei JP, Zhang CD, Fu X, et al. A novel TNM classification for colorectal cancers based on the metro-ticket paradigm[J]. J Cancer, 2021, 12(11):3299-3306.DOI:10.7150/jca.55097. Cited in this article [1]

[17]	Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics,2020[J]. CA Cancer J Clin, 2020, 70(3):145-164.DOI:10.3322/caac.21601. Cited in this article [1]

[18]	Spaander MCW, Zauber AG, Syngal S, et al. Young-onset colorectal cancer[J]. Nat Rev Dis Primers, 2023, 9(1):21.DOI:10.1038/s41572-023-00432-7. Cited in this article [1]

[19]	Cucciniello L, Gerratana L, Puglisi F. Liquid biopsy,an everchanging balance between clinical utility and emerging technologies[J]. Cancers(Basel), 2022, 14(17):4277.DOI:10.3390/cancers14174277. Cited in this article [1]

[20]	Basile D, Gallois C, Puglisi F, et al. Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients:a bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey[J]. Clin Res Hepatol Gastroenterol, 2021, 45(3):101681.DOI:10.1016/j.clinre.2021.101681. Cited in this article [1]

[21]	Blockus H, Chédotal A. Slit-robo signaling[J]. Development, 2016, 143(17):3037-3044.DOI:10.1242/dev.132829. Cited in this article [1]

[22]	O’Donnell MP, Bashaw GJ. Distinct functional domains of the abelson tyrosine kinase control axon guidance responses to netrin and slit to regulate the assembly of neural circuits[J]. Development, 2013, 140(13):2724-2733.DOI:10.1242/dev.093831. Cited in this article [1]

[23]	Yang L, Bashaw GJ. Son of sevenless directly links the robo receptor to rac activation to control axon repulsion at the midline[J]. Neuron, 2006, 52(4):595-607.DOI:10.1016/j.neuron.2006.09.039. Cited in this article [1]

[24]	Legg JA, Herbert JM, Clissold P, et al. Slits and roundabouts in cancer,tumour angiogenesis and endothelial cell migration[J]. Angiogenesis, 2008, 11(1):13-21.DOI:10.1007/s10456-008-9100-x. Cited in this article [1]

[25]	Dickson BJ, Gilestro GF. Regulation of commissural axon pathfinding by slit and its robo receptors[J]. Annu Rev Cell Dev Biol, 2006, 22:651-675.DOI:10.1146/annurev.cellbio.21.090704.151234. Cited in this article [1]

[26]	Gröne J, Doebler O, Loddenkemper C, et al. ROBO1/ROBO4:differential expression of angiogenic markers in colorectal cancer[J]. Oncol Rep, 2006, 15(6):1437-1443. Cited in this article [1]

[27]	Huminiecki L, Gorn M, Suchting S, et al. Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis[J]. Genomics, 2002, 79(4):547-552.DOI:10.1006/geno.2002.6745. Cited in this article [1]

[28]	Pircher A, Fiegl M, Untergasser G, et al. Favorable prognosis of operable non-small cell lung cancer(NSCLC) patients harboring an increased expression of tumor endothelial markers(TEMs)[J]. Lung Cancer, 2013, 81(2):252-258.DOI:10.1016/j.lungcan.2013.04.014. Cited in this article [1]

[29]	Hayashi S, Takeichi M. Emerging roles of protocadherins:from self-avoidance to enhancement of motility[J]. J Cell Sci, 2015, 128(8):1455-1464.DOI:10.1242/jcs.166306. Cited in this article [1]

[30]	Liu R, Yang X, Quan Y, et al. Pivotal models and biomarkers related to the prognosis of breast cancer based on the immune cell interaction network[J]. Sci Rep, 2022, 12(1):13673.DOI:10.1038/s41598-022-17857-x. Cited in this article [1]